Research
Hormonal
The efficacy of GLP-1RA combined with lifestyle modification is influenced by treatment duration, drug type (semaglutide/tirzepatide), dosing frequency (weekly), and geographic region (North America).
For the best weight loss results with GLP-1RAs, choose a weekly formulation (like semaglutide or tirzepatide) if possible, maintain the treatment for at least a year, and ensure your lifestyle intervention is consistent. Regional factors may also play a role in outcomes.
GoodQualifiesMEDIUM confidence
Longer treatment duration, use of semaglutide or tirzepatide, weekly dosing, and studies conducted in North America showed more pronounced weight loss effects.
Why this rating
Based on subgroup analysis of 33 RCTs.
Source
Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis
Jiaheng Chu et al. · EClinicalMedicine · 2025
DOI 10.1016/j.eclinm.2025.103464
Meta-analysis · 33 studiesCited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →